Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh® (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's disease in adults.

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.

FDA approves Eli Lilly's Omvoh for Crohn's disease, showing strong Phase 3 results in clinical remission and intestinal healing over two years.

The U.S. Food and Drug Administration has approved Eli Lilly's Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's disease in adults.

Indianapolis-based Lilly announced Thursday that the U.S. Food and Drug Administration has approved Omvoh for the treatment of moderately to severely active Crohn’s disease in adults. Omvoh is now approved in the U.

The FDA has approved Omvoh (mirikizumab-mrkz) for treating moderately to severely active Crohn’s disease in adults. Clinical trials demonstrated significant results, with 53 per cent achieving clinical remission at one year.

The drug is already approved in the US to treat ulcerative colitis, another form of inflammatory bowel disease

The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second interleukin-23p19 specific inhibitor approved for both major types of inflammatory bowel disease,